, and later the term 'Orteca' virus was suggested for this virus isolated from monkey outbreaks in Oregon, Texas and California (Nicholas, I97o a) . As this virus is identical with Tanapox, this latter name has been suggested as the most appropriate designation for the virus (Downie & Espafia, I97Z ). An outbreak of Yaba infection was first reported in a colony of rhesus monkeys housed in outdoor pens at Yaba near Lagos in West Africa (Bearcroft & Jamieson, I958) and was later shown to be caused by a pox virus (Niven et al. I961 ).
Yaba and Tanapox are then primarily diseases of monkeys and the causal viruses are similar in morphology and resemble vaccinia (de Harven & Yohn, 1966; Espafia, Brayton & Ruebner, 1971) . Both viruses may infect man (for Yaba, see Grace & Mirand, 1963) and although the lesions in rhesus monkeys show a superficial resemblance they are histologica1Iy quite distinct. Those produced by Tanapox virus show hypertrophy and thickening of the epithelial layers of the skin with swelling and ballooning of the deeper epithelial cells which show vacuolation of cell nuclei and eosinophilic cytoplasmic inclusions (McNulty et al. I968; Downie et al. I97I) . There is little cellular infiltration in the underlying dermis. The lesions of Yaba infection show tumour-like masses of polygonal mononuclear cells and later infiltration with lymphocytes and polymorphonuclear leucocytes (Niven et al. I96I) . Eosinophilic cytoplasmic inclusions are present in the cytoplasm of the 'tumour cells' but there is no nuclear vacuolation and the overlying epithelium is not involved in the hyperplastic process. Some degree of cross-immunity in monkeys recovered from Tanapox and Yaba infections has been noted (Kupper et al. I97O ) and serological cross-reactions between the viruses have been observed (Nicholas & McNulty, I968; Yohn, quoted by Crandell et al. I969; Nicholas, I97ob) . This paper presents a comparative study of these two viruses.
METHODS
Virus strains. The Tanapox virus isolated in I962 had been passed three times in tissue cultures of human thyroid, four times in human amnion, nine times in W.I. cells (a continuous cell line derived from human embryo lung) and three or four times in Vero cells before being used in the tests described below. The Yaba tumour virus was received from Dr Allison of the National Institute for Medical Research in I97o as a piece of tumour tissue removed from an experimentally infected rhesus monkey. This virus has been used to infect further rhesus monkeys and has been passed three times in tissue cultures in Vero cells and four times in cultures of BSC-I monkey cell line.
Tanapox virus for neutralization tests and antigen for complement fixation and precipitation tests were prepared from tissue cultures of Vero or BSC-I cells in 12 oz bottles as described previously (Downie & Espafia, 1972) . The cells were collected from virus-infected cultures after 8 to I2 days, suspended in M[25 o McIlvaine's citric acid phosphate buffer, pH 7"2, and disrupted by ultrasonic vibration for 3 ° s by a 5o W Mullard ultrasonic disintegrator. Cell debris was removed by centrifuging at low speed and the supernatant fluid centrifuged in a Spinco model L2 centrifuge at I5ooog for 3o rain. The supernatant fluid containing approximately o.2 ~ of the original virus was kept as antigen. The virus deposit was resuspended in M/25O buffer and again centrifuged at 15 ooo g for 30 rain. This final deposit suspended in M/250 buffer was kept frozen at -7o °C as stock virus suspension. Suspensions of Tanapox virus for immunization of monkeys were prepared in the same way from Vero cells grown in Medium 199 with vervet monkey serum instead of foetal calf serum; the virus suspension was then partly purified by layering it on 35 ~ sucrose solution and centrifuging in an MSE model Superspeed 65 centrifuge for 90 min at 2oooog. The deposit was suspended in M/250 buffer and centrifuged at I5ooog for 30 min; the resuspended deposit was used for immunizing injections.
Yaba virus used to infect and to immunize monkeys was prepared from Yaba lesions produced in rhesus monkeys. The 'tumour' tissue was finely minced, suspended in M/25O buffer and treated in an MSE tissue homogeniser for 5 rain. Preparation of antisera. Tana virus for absorption of sera was prepared from I7 I2 oz bottles of BSC-I cells, heavily seeded with virus and grown for 7 days at 35 °C. The virus was partially purified by differential sedimentation as described above and suspended in I4 ml of PBS. Yaba virus for this purpose was similarly prepared from about 5 g of 23-day Yaba' tumour' tissue. Sera were obtained from monkeys which had recovered from infection induced by intradermal injection of virus at 4 to 12 sites made I9 to 5o days previously. High-titre sera were prepared by giving two or three subsequent intravenous injections of concentrated virus to such animals at 6-day intervals. The monkeys were bled 6 days after the last intravenous injection.
Serological tests. Complement fixation, neutralization and precipitation in agar-gel tests were made as described previously for Tanapox virus (Downie & Espafia, I972) . As noted above, Yaba antigen for complement fixation and precipitation tests was prepared from the tumour-like lesions in rhesus monkeys: virus for neutralization tests was prepared from cultures of BSC-I cells. In these tests equal volumes of serum dilutions and virus suspension were mixed in tubes which were then held at 36 °C in a water bath for 2 h before inoculation of o.2 ml of each mixture into each of 3 or 4 BSC-I cell cultures grown in Leighton tubes. The virus suspension used was such that o-2 ml of normal serum-virus mixtures would produce 5o to ioo lesions in control tubes. Lesions in tissue culture tubes with Tanapox virus were counted after 7 to Io days incubation and in tests with Yaba virus after ~o to 13 days. At first lesions were counted with a microscope at a magnification of × I o; in later tests the medium was removed from the tubes, the cell sheets were stained with I ~o methyl violet or strong carbol fuchsin for 2 min and the lesions counted with a hand lens. From the resulting counts the neutralization titre of sera was estimated as that dilution of serum which would reduce the lesion count to 5o ~ of the controls.
RESULTS

Lesions produced in rhesus monkeys
The lesions produced by inoculation of Tanapox virus (IO a to Io G TCD 5o) intradermally into rhesus monkeys usually appear in 3 or 4 days, reach a maximum size of about I "5 cm in diameter after 7 to I4 days and thereafter regress. The lesions of Yaba virus with similar doses become apparent as small nodules in 7 to Io days, increase in size to form markedly raised tumour masses up to 4 or 5 cm in diameter in 3 to 6 weeks and then slowly regress and disappear in Io to 12 weeks. Figs. I and 2 show the lesions produced by these two viruses I I and 23 days after intradermal inoculation into a rhesus monkey.
Growth in tissue culture
Both viruses grow only in cell cultures derived from human and monkey tissues. Yaba virus is more fastidious in growth requirements in that it does not produce cytopathic effects in certain cell lines such as HeLa, MA-Io 4 (embryonic rhesus kidney), MA-I2z (embryonic African green monkey gonads) and primary cynomolgus kidney cell cultures which will support the growth of Tanapox virus. In susceptible cell lines such as BSC-r, Yaba virus produces cytopathic effects more slowly than does Tanapox virus with similar infecting doses; the lesions also differ in appearance. Tanapox 
Active immunity experiments
In Liverpool two rhesus monkeys, Rh2 and Rho38, had been injected intradermally at ten sites on the back with Tanapox virus prepared from tissue cultures of Veto cells and 3 weeks later, when the skin lesions had healed, they were given the first of three intravenous injections of purified virus. The second and third intravenous injections were given 6 and I2 days later. These two animals along with three Yaba immune monkeys and a normal control were challenged by the intradermal injection of Yaba and Tanapox virus as described below. Rh2 had received its original intradermal injections 9 months and Rho38 2 months before the tests for immunity to the two viruses.
Three rhesus monkeys, Rho24, Rho37 and Rh4, had been infected by eight intradermal injections of Yaba virus. Rh4 had two intravenous injections of purified virus 6 and 7 weeks later. Two months after the original infections when the Yaba lesions were regressing, all three animals were challenged by intradermal injection of Tanapox and Yaba viruses along with the two Tanapox immunized animals and the normal control. The Tanapox virus used for challenge was prepared from tissue cultures and had a TCD5o of about IoT/ml. The Yaba virus was prepared from an I8-day lesion in a rhesus monkey and had a TCD5o of Io5/ml.
The results of these experiments are summarized in Table I . It will be seen that there were no lesions in the animals challenged with the immunizing virus. There is apparently some degree of immunity to the heterologous virus as indicated by the absence of lesions (Rh4) or the trivial nature of the lesions (Rho24 and Rho37) or the delayed appearance and smaller lesions as compared with the control (Rh2 and Rho38).
In the Davis laboratories, rhesus monkeys were inoculated intradermally (Tanapox) or subcutaneously (Yaba) with either skin lesion suspensions or tissue culture virus. In general, animals were inoculated at three sites on the shaved flanks with o.2 ml of a virus preparation containing approximately Io 3 TCD5o/injection. The animals showed lesions at the sites of inoculation as described above.
Animals were challenged at the time of regression of lesions by intradermal or subcutaneous inoculation at three sites on the shaved back or abdomen with Io 3 to Io ~ TCD 5o of the heterologous virus. As infectivity control of the challenge virus, three animals free of antibody against either virus were inoculated simultaneously with the same dose of virus.
The results of these experiments indicate that monkeys recovering from Tanapox infections were only partially resistant to Yaba virus inoculation (Table 2A ). This partial protection was manifested by a marked delay in the time of appearance and decreased size of the lesions. On the other hand, Yaba immune monkeys were fully resistant to challenge inoculation of Tanapox virus (Table 2B) . In order to determine whether repeated inoculations of Tanapox virus produced a stronger immunity in monkeys against Yaba virus, six rhesus monkeys were inoculated intradermally with Tanapox virus and 4 weeks later, after the lesions had healed, they were given three intravenous injections, at weekly intervals, of Io 7 TCD 5o of Tanapox virus and challenged 7 days later with IO ~ TCD5o of Yaba virus. Whereas the infectivity controls developed large lesions at all three sites of inoculation within 9 to I I days, no lesions were observed in the Tana immunized monkeys for a period of 3 months after challenge.
Serological tests Complement fixation tests
'Soluble' antigens prepared from infected cells were used at optimal dilution, i.e. the highest dilution which gave maximal titre with a homologous immune monkey serum in a chessboard titration. The results of tests on four Tanapox antisera and four Yaba antisera are shown in Table 3 . All four monkeys providing the Tanapox antisera had been given three intravenous injections of concentrated Tanapox virus suspension 3 weeks after multiple intradermal injections of this virus. The first three Yaba antisera were obtained from rhesus monkeys bled 4 (A I I) or 6 weeks (Rho24 and Rho37) after 'tumours' had been produced by intradermal or subcutaneous injection of virus. The fourth anti-Yaba serum was obtained from a rhesus monkey which had developed Yaba 'tumours' after intradermal injection and 5 and 6 weeks later was given intravenous injections of concentrated virus prepared from monkey' tumour' cells.
It is apparent from the results in Table 3 that there is complement fixation to lower titre with the heterologous antigen with both sets of sera. The anti-Yaba serum giving the highest CF titre was from the monkey that received intravenous injections of virus when its lesions were regressing. In Davis, a study was carried out to confirm antigenic relationships between four virus isolates of Tanapox virus and two of Yabapox virus. Complement fixing antigens were prepared as described above from monkey skin lesions and infected tissue cultures. The virus isolates used in these studies are listed in Table 4 -The results of repeated tests showed that the degree of antigenic crossing between the Yaba and Tanapox virus was dependent upon the type of complement fixing antigen used. There was an extensive overlapping if monkey lesions were used as a source of antigen. Virus antigens prepared from tissue culture, on the other hand, reacted only against the homologous antiserum. Similar results were obtained with serial bleedings from rhesus monkeys which had been inoculated with either Tanapox CF titre with monkey antisera against or Yaba virus. Table 5 shows the immune response of rhesus monkeys to either virus as measured by complement fixation and the cross-reactions obtained with antigens from monkey lesions and from virus infected tissue cultures. It will be noticed that again antigens from monkey lesions give some crossing with the heterologous serum whereas antigens prepared from tissue culture do not. The lower potency of the latter antigens, especially of Yaba virus, may have been partly responsible for this difference. However, although there is an extensive overlapping between Tana and Yaba viruses, the homologous titres are sufficiently higher to permit their separation.
Precipitation tests
Tests in agar gel were made against Tanapox and Yaba antigens using the anti-Tana serum from Vervet 2 and the anti-Yaba from Rh 4. These monkey sera did not show strong reactions but the results of one test are shown in Fig. 5 . Serum from vervet 2 shows lines of precipitation with both antigens but the marked spur suggests that although the two viruses have a common antigen, Tanapox has an antigen lacking in Yaba. Similarly, the reactions with serum Rh 4 indicate the presence of common antigens but one line between the serum and Yaba antigen is not present between the serum and Tana antigen suggesting the absence of an antigen from Tana virus which is present in Yaba.
Neutralization tests
The results of neutralization tests with Tana and Yaba monkey antisera are shown in Table 6 . The tests were made in cultures of BSC-I cells in Leighton tubes and the viruses used were also obtained from virus-infected BSC-I cells.
The results in Table 6 show much lower neutralization titres to the heterologous virus with the exception of Vervet 2 serum. The serum from this m o n k e y before inoculation neutralized T a n a p o x virus to a titre of I/6o and Y a b a virus to a titre o f I/3o; it was the only one of these animals which had a n t i b o d y to either virus before inoculation. The presence of pre-existing a n t i b o d y to Y a b a virus in this m o n k e y m a y have determined the high titre to this virus after immunization with T a n a p o x virus. W i t h this exception, the neutralization tests show more specificity than do the C F tests with these sera (Table 3) . 
Cross-absorption experiments
In the hope of clarifying the antigenic relationship between the two viruses absorptions of sera with concentrated suspensions of virus were made.
Four sera were absorbed with the two virus suspensions -Vervet 2, Rho38, RhAII and a normal control rhesus monkey serum Rho39 (serum Rh 4 had not been prepared at the time these absorption experiments were made). To o'4 ml quantities of serum 3"6 ml of virus suspension were added in two fractions on successive days. After absorption the serum virus suspensions were centrifuged at 15ooo g for 6o rain and the supernatant-absorbed sera removed. The absorbed and similarly diluted (I/tO) unabsorbed sera were then exposed in shallow layers to u.v. light for I2 rain and heated in a water bath at 59 °C for 3o min. Samples of the absorbed sera were tested in tissue culture for residual virus but none was recovered. The absorbed sera were tested along with the unabsorbed control sera for residual antibody.
Complement fixation tests with the sera absorbed with Yaba virus were unsatisfactory because these sera were highly anti-complementary. Absorption with Tanapox virus of Vervet 2 serum removed CF antibody to both viruses but did not reduce the titre of CF antibody (1/4o) for Yaba virus in RhA11 serum. Precipitation tests with the absorbed sera gave inconclusive results. This Yaba antiserum before absorption failed to precipitate with either antigen and the Tanapox antiserum failed to show precipitation with either antigen after absorption with either virus. All sera absorbed with Yaba virus contained excess Yaba antigen which showed lines of precipitation with unabsorbed Tanapox antiserum, and this may have made these sera anti-complementary. The presence of excess antigen in the Tanapox antiserum absorbed with Yaba virus may have inhibited precipitation of this absorbed antiserum with Tanapox antigen.
The results of neutralization tests of the absorbed and unabsorbed sera are shown in Table 7 . It can be seen that absorption of the two anti-Tana sera with Tana virus removed neutralizing antibodies to both viruses. Absorption of these sera with Yaba virus removed neutralizing antibodies for itself but only slightly reduced the titre of neutralizing antibody for Tana virus. The anti-Yaba serum had very little neutralizing antibody for Tanapox virus before absorption. Absorption with Yaba virus removed the antibody to Yaba but absorption with Tanapox virus had no effect on the anti-Yaba titre. These absorption experiments suggest that much of the neutralizing antibody for each virus is relatively specific to itself. (I97I) and Espafia (I97I) failed to obtain such cross-reactions in complement fixation tests, but these authors used immune monkey sera whereas Nicholas used antisera prepared in rabbits against viruses prepared in tissue culture, which may serve to account for the partial crossreactions which she obtained. Similarly, Nicholas (I97ob) found that her anti-Yaba and anti-Tana sera fixed complement with swinepox antigen and neutralized swinepox virus to low titre. The only swinepox antiserum that we have had available, prepared by immunizing rabbits with tissue-culture-grown virus, failed to exhibit cross-reactions with Tanapox virus in complement fixation and neutralization tests. Swinepox virus grows slowly in tissue culture (Nicholas, I97oa) and the lesions in infected animals are histologically similar to Tanapox, showing nuclear vacuolation and cytoplasmic inclusions. However, neither Tana nor Yaba viruses grow in tissue culture of porcine kidney (Nicholas, I97oa) and we have failed to infect piglets by injections of high-titre Tanapox virus suspensions (Downie et al. I97I) . The relationship of swinepox to Tanapox and Yaba viruses may not therefore be very close.
In cross-immunity experiments in monkeys Kupper et al. (I97o) found that monkeys infected with Yaba virus were immune to Tanapox injections made 66 days later. On the other hand, monkeys tested with Yaba virus 66 days after infection with Tanapox showed lesions at all ten inoculation sites, although the lesions appeared a day or two later than those in control animals. Our own results are essentially in agreement with this. Sixteen monkeys recovered from experimental Tanapox infection were only partially resistant to inoculation with Yaba virus, as shown by a delay in the appearance and the severity of the lesions when compared with controls. However, this protection could be markedly enhanced by repeated intravenous inoculations of high doses of Tana virus. In one experiment in Davis, six monkeys, which were immunized with Tanapox virus by repeated intravenous injections given 3 weeks after the initial intradermal inoculation and showed high CF titres (I : I28 to 1:256), were fully resistant when challenged with Yaba virus. On the other hand, of 14 Yaba convalescent monkeys challenged with Tanapox virus, two showed trivial evanescent lesions and 12 were immune. Serological tests with monkey antisera to the two viruses showed some cross-reactivity in complement fixation tests but titres against heterologous antigens were 4 to 8 times lower than those against the homologous antigens. By neutralization tests in tissue culture cross-reactivity was again demonstrable. Precipitation in agar-gel tests indicated that each of the two viruses possessed, in addition to a common antigen, an antigen specific to itself. Cross-absorption tests confirmed antigenic dissimilarity between the two viruses in that sera absorbed with the heterologous virus still contained neutralizing antibody for the homologous virus only slightly reduced in titre.
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